US equities |
NVDA $168.25 ▼-5.83% AMD $517.64 ▲+1.78% MU $710.99 ▼-3.02% SPCX $141.63 ▼-0.31% SNDK $847.16 ▼-4.44% TSLA $376.10 ▼-0.52% AVGO $326.10 ▲+2.07% AMZN $269.12 ▲+0.82%
FinancialContent

Harrow, Inc. - Common Stock (NQ:HROW)

31.31 +3.84 (+13.98%)
Delayed Quote Updated: 11:39 AM EST, Nov 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Harrow, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Harrow Q3 Earnings Call Highlights ↗
Harrow (NASDAQ:HROW) reported record third-quarter revenue and reaffirmed its full-year sales forecast, but sharply reduced its adjusted earnings outlook as lower-than-expected margins and accelerated... 
Via MarketBeat
Topics Earnings
Premarket Movers Nov. 10, 2026: Gainers and Losers ↗
Via Chartmill
Nov. 9 After-Hours Movers: Gainers and Losers ↗
Via Chartmill
News headline image
PHIL Partners with Harrow to Power HarrowRx, One Prescribing Destination for Harrow’s Eye Care Portfolio
From PHIL Inc.
Via Business Wire
Harrow Inc (NASDAQ:HROW): An Affordable Growth Play Combining Rapid Expansion with Reasonable Valuation ↗
Via Chartmill
Harrow Inc (NASDAQ:HROW) Q1 2026 Results Miss Estimates, Revenue and Earnings Fall Short ↗
Via Chartmill
Harrow Inc (NASDAQ:HROW) Screens as a Strong Growth Stock with a Bullish Technical Setup ↗
Via Chartmill
News headline image
Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half ↗
Harrow (NASDAQ: HROW) posts positive study results for IHEEZO ophthalmic gel, significantly reducing IVT injection patient discomfort. 
Via Benzinga
News headline image
Harrow (HROW) Q2 2026 Earnings Call Transcript ↗
Revenue hit $70.7M with guidance raised to $350M-$365M for full year. 
Via The Motley Fool
Topics Earnings
News headline image
Harrow Q2 Earnings Call Highlights ↗
Harrow (NASDAQ:HROW) reported second-quarter revenue of $70.7 million, up 11% from a year earlier and about 60% sequentially, as the ophthalmic pharmaceutical company said it entered the second half of... 
Via MarketBeat
Topics Earnings
News headline image
Harrow (HROW) Q1 2026 Earnings Transcript ↗
Harrow (HROW) Q1 2026 Earnings Transcript 
Via The Motley Fool
Harrow Inc (NASDAQ:HROW) Presents a Compelling Case for Affordable Growth ↗
Via Chartmill
News headline image
Harrow Q1 Earnings Call Highlights ↗
Harrow (NASDAQ:HROW) executives said the company’s first-quarter results were weighed down by a discrete revenue issue tied to VEVYE coverage and high-deductible patients, but management repeatedly... 
Via MarketBeat
Topics Earnings
News headline image
Harrow Inc (NASDAQ:HROW) Presents a Growth and Breakout Opportunity ↗
Harrow Inc. (HROW) combines explosive projected earnings growth with a technical chart setup suggesting a potential breakout, aligning fundamentals with price action. 
Via Chartmill
HARROW INC (NASDAQ:HROW): A GARP Stock with Strong Growth at a Reasonable Price ↗
Via Chartmill
News headline image
A Major Investor Just Sold $7.8 Million in Harrow Stock -- Is This a Sell Signal? ↗
This ophthalmic pharma specialist -- known for its compounded medications and royalty streams -- just reported a big insider sale. 
Via The Motley Fool
Topics Regulatory Compliance
Harrow Inc (NASDAQ:HROW) Stock Plummets 13% After Q4 Earnings Miss ↗
Via Chartmill
HARROW INC (NASDAQ:HROW) Emerges as a High-Growth Momentum Stock with Strong Technical Setup ↗
Via Chartmill
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗
Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗
Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market. 
Via The Motley Fool
Topics Regulatory Compliance
What's going on in today's session ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Harrow (HROW) Q4 2025 Earnings Call Transcript ↗
Harrow (HROW) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Which stocks are gapping on Tuesday? ↗
Via Chartmill
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
Private Equity-Style Fund Buys $15.7 Million in Harrow Stock as Revenue Jumps 45% ↗
Harrow’s accelerating revenue and expanding product portfolio may help explain why a fundamentals-focused investment firm just made it a new position. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Outset Medical, Gemini Space Station, CoreWeave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
These stocks are moving in today's after hours session ↗
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Could Harrow's New Sedation Pill Change Millions Of Medical Procedures Forever? ↗
Harrow, Inc. (NASDAQ: HROW), a U.S.-based provider of ophthalmic disease management solutions, announced on Friday that it has agreed to acquire Melt 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >